MOLN Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -2841.85%. Molecular Partners AG's return on equity of -37.36% beat Addex Therapeutics's return on equity of 91.08%.

Molecular Partners AG has a consensus price target of $10.85, signalling upside risk potential of 197.38%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 239.75%. Given that Addex Therapeutics has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics is more attractive than Molecular Partners AG.

Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.646, suggesting its more volatile than the S&P 500 by 64.6%.

Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

Molecular Partners AG quarterly revenues are $787.5K, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Molecular Partners AG's net income of -$18.6M is lower than Addex Therapeutics's net income of -$1.6M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is 1.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.81x versus 24.16x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -106.6%. Molecular Partners AG's return on equity of -37.36% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Molecular Partners AG has a consensus price target of $10.85, signalling upside risk potential of 197.38%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.80 which suggests that it could grow by 48.34%. Given that Molecular Partners AG has higher upside potential than CRISPR Therapeutics AG, analysts believe Molecular Partners AG is more attractive than CRISPR Therapeutics AG.

Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

Molecular Partners AG quarterly revenues are $787.5K, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. Molecular Partners AG's net income of -$18.6M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.81x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of --. Molecular Partners AG's return on equity of -37.36% beat NLS Pharmaceutics's return on equity of --.

Molecular Partners AG has a consensus price target of $10.85, signalling upside risk potential of 197.38%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 10566.67%. Given that NLS Pharmaceutics has higher upside potential than Molecular Partners AG, analysts believe NLS Pharmaceutics is more attractive than Molecular Partners AG.

Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

Molecular Partners AG quarterly revenues are $787.5K, which are larger than NLS Pharmaceutics quarterly revenues of --. Molecular Partners AG's net income of -$18.6M is higher than NLS Pharmaceutics's net income of --. Notably, Molecular Partners AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.81x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -2408.81% compared to Molecular Partners AG's net margin of 0.11%. Molecular Partners AG's return on equity of -37.36% beat BeOne Medicines's return on equity of -11.54%.

Molecular Partners AG has a consensus price target of $10.85, signalling upside risk potential of 197.38%. On the other hand BeOne Medicines has an analysts' consensus of $332.60 which suggests that it could grow by 19.14%. Given that Molecular Partners AG has higher upside potential than BeOne Medicines, analysts believe Molecular Partners AG is more attractive than BeOne Medicines.

Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

Molecular Partners AG quarterly revenues are $787.5K, which are smaller than BeOne Medicines quarterly revenues of $1.1B. Molecular Partners AG's net income of -$18.6M is lower than BeOne Medicines's net income of $1.3M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.81x versus 7.17x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.